The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs.

Register Below

This ASCO26 Poster Walkthrough group will explore key findings from the following posters:

Poster #1073: (RW) post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) in US.

Poster #1648: Survival outcomes with immune checkpoint inhibitors among patients with cancer from minoritized racial and ethnic groups: A systematic review and meta-analysis.

Track: Breast Cancer—Metastatic, Care Delivery/Models of Care |  Subtrack: Hormone Receptor-Positive (HR+), Discrepancies in Care |  Keywords: Real-world outcomes, Racial disparities